Search research articles
Contact Us
Filters
Showing results (431-440 of 580) with videos related to
Page
of 58
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu, Junya Yan, Qian Guo, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
JAAD International
|
March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Xue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Page
of 58
Search research articles
Search
Showing results (431-440 of 580) with videos related to
Sort By:
Page
of 58
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Jiayi Yu, Junya Yan, Qian Guo, et al.
The Lancet. Oncology
|
September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Cell Reports
|
April 22, 2014
Isolation and molecular characterization of circulating melanoma cells
Xi Luo, Devarati Mitra, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)
Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
EMBO Molecular Medicine
|
June 14, 2017
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
Michael P Smith, Emily J Rowling, Zsofia Miskolczi, et al.
JAAD International
|
March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study
Xue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
Cancer
|
August 6, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience
Jason J Luke, Margaret K Callahan, Michael A Postow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
Page
of 58